Broadening the clinical use of platinum drug–based chemotherapy with new analogues

Bibliography

• HARRAP KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. (1985) 12:21-33.
   PubMed Web of Science ®Google Scholar
• ADAMS M, CALVERT AH, CARMICHAEL J et al.: Chemotherapy for ovarian cancer – a consensus statement on standard practice. Br. J. Cancer (1998) 78:1404-1406.
   PubMed Web of Science ®Google Scholar
• KELLAND LR: New platinum antitumor complexes. Crit. Rev. Oncol./Hematol. (1993) 15:191-219.
   PubMed Web of Science ®Google Scholar
• KELLAND LR: Overcoming resistance to platinum therapy in patients with advanced cancer. Am. J. Cancer (2002) 1:247-255.
   Google Scholar
• GIACCHETTI S, PERPOINT B, ZIDANI N et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. (2000) 18:136-147.
   PubMed Web of Science ®Google Scholar
• DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. (2000) 18:2938-2947.
   PubMed Web of Science ®Google Scholar
• ROTHENBERG ML, OZA AM, BIGELOW RH et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. (2003) 21:2059-2069.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:23-29.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, ABEL G, McKEAGE MJ et al.: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res. (1993) 53:2581-2586.
   PubMed Web of Science ®Google Scholar
• HOLFORD J, SHARP SY, MURRER BA, ABRAMS M, KELLAND LR: In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer (1998) 77:366-373.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, BARNARD CFJ, MELLISH KJ: A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. (1994) 54:5618-5622.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, JONES M, GWYNNE JJ et al.: Antitumour activity of orally administered ammine/amine platinum (IV) dicarboxylate complexes against a panel of human ovarian carcinoma xenografts. Int. J. Oncol. (1993) 2:1043-1048.
   PubMed Web of Science ®Google Scholar
• McKEAGE MJ, MORGAN SE, BOXALL FE, MURRER BA, HARD GC, HARRAP KR: Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br. J. Cancer (1993) 67:996-1000.
   PubMed Web of Science ®Google Scholar
• McKEAGE MJ, BOXALL FE, JONES M, HARRAP KR: Lack of neurotoxicity of oral bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res. (1994) 54:629-631.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ, MORGAN SE, BOXALL FE, MURRER BA, HARD GC, HARRAP KR: Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum (IV) dicarboxylates. Cancer Chemother. Pharmacol. (1994) 33:497-503.
   PubMed Web of Science ®Google Scholar
• McKEAGE MJ, KELLAND LR, BOXALL FE et al.: Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) in vivo. Cancer Res. (1994) 54:4118-4122.
   PubMed Web of Science ®Google Scholar
• KELLAND LR: An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin. Investig. Drugs (2000) 9(6):1373-1382.
   PubMed Web of Science ®Google Scholar
• POON GK, RAYNAUD FI, MISTRY P et al.: Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatog. A (1995) 712:61-66.
   PubMed Web of Science ®Google Scholar
• RAYNAUD FI, BOXALL FE, GODDARD P, BARNARD CF, MURRER BA, KELLAND LR: Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res. (1996) 16:1857-1862.
   PubMed Web of Science ®Google Scholar
• RAYNAUD FI, MISTRY P, DONAGHUE A et al.: Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother. Pharmacol. (1996) 38:155-162.
   PubMed Web of Science ®Google Scholar
• RAYNAUD FI, ODELL DE, KELLAND LR: Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Br. J. Cancer (1996) 74:380-386.
   PubMed Web of Science ®Google Scholar
• ANDO Y, SHIMIZU T, NAKAMURA K et al.: Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br. J. Cancer (1998) 78:1170-1174.
   PubMed Web of Science ®Google Scholar
• CARR JL, TINGLE MD, MCKEAGE MJ: Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother. Pharmacol. (2002) 50:9-15.
   PubMed Web of Science ®Google Scholar
• CARR JL, TINGLE MD, MCKEAGE MJ: Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother. Pharmacol. (2006) 57:483-490.
   PubMed Web of Science ®Google Scholar
• SHARP SY, ROGERS PM, KELLAND LR: Transport of cisplatin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin. Cancer Res. (1995) 1:981-989.
   PubMed Web of Science ®Google Scholar
• SAMIMI G, HOWELL SB: Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother. Pharmacol. (2006) 57:781-788.
   PubMed Web of Science ®Google Scholar
• REARDON JT, VAISMAN A, CHANEY SG, SANCAR A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. (1999) 59:3968-3971.
   PubMed Web of Science ®Google Scholar
• O’NEILL CF, KOBERLE B, MASTERS JRW, KELLAND LR: Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br. J. Cancer (1999) 81:1294-1303.
   PubMed Web of Science ®Google Scholar
• FINK D, NEBEL S, AEBI S et al.: The role of DNA mismatch repair in platinum drug resistance. Cancer Res. (1996) 56:4881-4886.
   PubMed Web of Science ®Google Scholar
• MELLISH KJ, KELLAND LR: Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV) (JM216) in two human ovarian carcinoma cell lines. Cancer Res. (1994) 54:6194-6200.
   PubMed Web of Science ®Google Scholar
• SAMIMI G, KISHIMOTO S, MANOREK G, BREAUX JK, HOWELL SB: Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother. Pharmacol. (2007) 59:301-312.
   PubMed Web of Science ®Google Scholar
• McKEAGE MJ, MISTRY P, WARD J et al.: A Phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother. Pharmacol. (1995) 36:451-458.
   PubMed Web of Science ®Google Scholar
• McKEAGE MJ, RAYNAUD F, WARD J et al.: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J. Clin. Oncol. (1997) 15:2691-2700.
   PubMed Web of Science ®Google Scholar
• BEALE P, RAYNAUD F, HANWELL J et al.: Phase I study of oral JM216 given twice daily. Cancer Chemother. Pharmacol. (1998) 42:142-148.
   PubMed Web of Science ®Google Scholar
• SESSA C, MINOIA C, RONCHI A et al.: Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann. Oncol. (1998) 9:1315-1322.
   PubMed Web of Science ®Google Scholar
• JUDSON I, CERNY T, EPELBAUM R et al.: Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann. Oncol. (1997) 8:604-606.
   PubMed Web of Science ®Google Scholar
• FOKKEMA E, GROEN HJ, BAUER J, UGES DR, WEIL C, SMITH IE: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small cell lung cancer. J. Clin. Oncol. (1999) 17:3822-3827.
   PubMed Web of Science ®Google Scholar
• TRUDEAU M, STUART G, HIRTE H et al.: A Phase II study of JM216 in cervical cancer: an NCIC CTG study. Gynecol. Oncol. (2002) 84:327-331.
   PubMed Web of Science ®Google Scholar
• FOKKEMA E, DE VRIES EGE, MEIJER S, GROEN HJM: Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother. Pharmacol. (2000) 45:89-92.
   PubMed Web of Science ®Google Scholar
• DE MARIO MD, RATAIN MJ, VOGELZANG NJ et al.: A Phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother. Pharmacol. (1999) 43:385-388.
   PubMed Web of Science ®Google Scholar
• JONES S, HAINSWORTH J, BURRIS HA III et al.: Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. Invest. New Drugs (2002) 20:55-61.
   PubMed Web of Science ®Google Scholar
• AMORINO GP, MOHR PJ, HERCULES SK, PYO H, CHOY H: Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother. Pharmacol. (2000) 46:423-426.
   PubMed Web of Science ®Google Scholar
• CHOY H: Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev. Anticancer Ther. (2006) 6:973-982.
   PubMed Web of Science ®Google Scholar
• GEORGE CM, HARAF DJ, MAUER AM et al.: A Phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest. New Drugs (2001) 19:303-310.
   PubMed Web of Science ®Google Scholar
• LATIF T, WOOD L, CONNELL C et al.: Phase II study of oral bis(aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer (HRPC). Invest. New Drugs (2005) 23:79-84.
   PubMed Web of Science ®Google Scholar
• STERNBERG CN, WHELAN P, HETHERINGTON J et al.: Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology (2005) 68:2-9.
   PubMed Web of Science ®Google Scholar
• HOLFORD J, RAYNAUD F, MURRER BA et al.: Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordinatiion complex, cis-[amminedichloro(2-methylpyridine)] platinum (II) (AMD473). Anticancer Drug Design (1998) 13:1-18.
   PubMedGoogle Scholar
• KAWAMURA-AKIYAMA Y, KUSABA H, KANZAWA F, TAMURA T, SAIJO N, NISHIO K: Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. Lung Cancer (2002) 38:43-50.
   PubMed Web of Science ®Google Scholar
• SHARP SY, SMITH V, HOBBS S, KELLAND LR: Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br. J. Cancer (1998) 78:175-180.
   PubMed Web of Science ®Google Scholar
• SHARP SY, O’NEILL CF, ROGERS PM, BOXALL F, KELLAND LR: Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur. J. Cancer (2002) 38:2309-2315.
   PubMed Web of Science ®Google Scholar
• HOLFORD J, BEALE PJ, BOXALL FE, SHARP SY, KELLAND LR: Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur. J. Cancer (2000) 36(15):1984-1990.
   PubMed Web of Science ®Google Scholar
• PESTELL KE, HOBBS SM, TITLEY JC, KELLAND LR, WALTON MI: Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol. Pharmacol. (2000) 57:503-511.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, BARNARD CDJ: AMD473. Drugs Future (1998) 23:1062-1065.
   Google Scholar
• RAYNAUD FI, BOXALL FE, GODDARD PM et al.: Cis-amminedichloro(2-methylpyridine) platinum (II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology and pharmacokinetics in mice. Clin. Cancer Res. (1997) 3:2063-2074.
   PubMed Web of Science ®Google Scholar
• LEYLAND-JONES B, KELLAND LR, HARRAP KR, HIORNS LR: Genomic imbalances associated with acquired resistance to platinum analogues. Am. J. Pathol. (1999) 155:77-84.
   PubMed Web of Science ®Google Scholar
• ROGERS P, BOXALL FE, ALLOT CP, STEPHENS TC, KELLAND LR: Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Eur. J. Cancer. (2002) 38:1653-1660.
   PubMed Web of Science ®Google Scholar
• KANZAWA F, AKIYAMA Y, SAIJO N, NISHIO K: In vitro effects of combinations of cis-amminedichloro(2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer (2003) 40:325-332.
   PubMed Web of Science ®Google Scholar
• PLASENCIA C, ABAD A, MARTINEZ-BALIBREA E, TARON M: Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. Invest. New Drugs (2004) 22:399-409.
   PubMed Web of Science ®Google Scholar
• RAAPHORST GP, YANG DP, LI LF, MALONE S: Comparison of human tumour cell responses to cisplatin and ZD0473 with and without irradiation. Anticancer Res. (2004) 24:613-618.
   PubMed Web of Science ®Google Scholar
• BEALE P, JUDSON I, O’DONNELL A et al.: A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). Br. J. Cancer (2003) 88:1128-1134.
   PubMed Web of Science ®Google Scholar
• TREAT J, SCHILLER J, QUOIX E et al.: ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur. J. Cancer (2002) 38:S13-S18.
   PubMedGoogle Scholar
• GORE ME, ATKINSON RJ, THOMAS H et al.: A Phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur. J. Cancer (2002) 38:2416-2420.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, O’BRIEN ME, BYRNE MJ, BARD M, KAUKEL E, SMIT B: Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur. J. Cancer (2002) 38:S19-S24.
   PubMed Web of Science ®Google Scholar
• GELMON KA, VANDENBERG TA, PANASCI L et al.: A Phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada clinical trials group trial, IND129. Ann. Oncol. (2003) 14:543-548.
   PubMed Web of Science ®Google Scholar
• TWELVES C, RECK M, ANTHONEY A, GATZEMEIER U, KAYE S: A Phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies. Cancer Chemother. Pharmacol. (2003) 52:277-281.
   PubMed Web of Science ®Google Scholar
• FLAHERTY KT, STEVENSON JP, REDLINGER M, ALGAZY KM, GIANTONIO B, O’DWYER PJ: A Phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemother. Pharmacol. (2004) 53:404-408.
   PubMed Web of Science ®Google Scholar
• GELMON KA, STEWART D, CHI KN et al.: A Phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada clinical trials group trial, IND131. Ann. Oncol. (2004) 15:1115-1122.
   PubMed Web of Science ®Google Scholar
• DOUILLARD JY, SCHILLER J: ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies. Eur. J. Cancer (2002) 38:S25-S31.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ: New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin. Investig. Drugs (2005) 14:1033-1046.
   PubMed Web of Science ®Google Scholar
• DRAGOVICH T, MENDELSON D, KURTIN S, RICHARDSON K, VON HOFF D, HOOS A: A Phase II trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother. Pharmacol. (2006) 58:759-764.
   PubMed Web of Science ®Google Scholar
• RADEMAKER-LAKHAI JM, TERRET C, HOWELL SB et al.: A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. (2004) 10:3386-3395.
   PubMed Web of Science ®Google Scholar
• RICE JR, GERBERICH JL, NOWOTNIK DP, HOWELL SB: Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin. Cancer Res. (2006) 12:2248-2254.
   PubMed Web of Science ®Google Scholar
• CAMPONE M, RADEMAKER-LAKHAI JM, BENNOUNA J et al.: Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother. Pharmacol. (2007) (In Press).
   Google Scholar
• ARMSTRONG DK, BUNDY B, WENZEL L et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. (2006) 354:34-43.
   PubMed Web of Science ®Google Scholar
• SANDLER A, GRAY R, PERRY MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med. (2006) 355:2542-2550.
   PubMed Web of Science ®Google Scholar
• PIETRAS RJ, FENDLY BM, CHAZIN VR, PEGRAM MD, HOWELL SB, SLAMON DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 9:1829-1838.
   PubMed Web of Science ®Google Scholar
• HURLEY J, DOLINY P, REIS I et al.: Docetaxel, cisplatin and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J. Clin. Oncol. (2006) 24:1831-1838.
   PubMed Web of Science ®Google Scholar
• BEUVINK I, BOULAY A, FUMAGALLI S et al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 120:747-759.
   PubMed Web of Science ®Google Scholar